naringenin has been researched along with Cardiac Hypertrophy in 3 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (66.67) | 24.3611 |
2020's | 1 (33.33) | 2.80 |
Authors | Studies |
---|---|
He, B; He, Y; Li, Y; Xia, T; Zeng, C; Zhang, C | 1 |
Ding, S; Huang, B; Huang, J; Jiang, Q; Qiu, H; Wu, Q; Zhang, J | 1 |
Ding, S; Huang, B; Huang, J; Jiang, Q; Qiu, H; Zhang, J; Zhou, P | 1 |
3 other study(ies) available for naringenin and Cardiac Hypertrophy
Article | Year |
---|---|
Naringenin Attenuates Isoprenaline-Induced Cardiac Hypertrophy by Suppressing Oxidative Stress through the AMPK/NOX2/MAPK Signaling Pathway.
Topics: AMP-Activated Protein Kinases; Animals; Cardiomegaly; Isoproterenol; Mice; Mice, Inbred C57BL; Myocytes, Cardiac; Oxidative Stress; Signal Transduction | 2023 |
Naringenin exhibits the protective effect on cardiac hypertrophy via EETs-PPARs activation in streptozocin-induced diabetic mice.
Topics: Animals; Cardiomegaly; Cardiotonic Agents; Diabetes Mellitus, Experimental; Diabetic Cardiomyopathies; Flavanones; Male; Myocardium; Peroxisome Proliferator-Activated Receptors; Up-Regulation | 2018 |
EETs/PPARs activation together mediates the preventive effect of naringenin in high glucose-induced cardiomyocyte hypertrophy.
Topics: Animals; Atrial Natriuretic Factor; Cardiomegaly; Cell Line; Diabetic Cardiomyopathies; Flavanones; Glucose; Myocytes, Cardiac; PPAR gamma; Rats; RNA, Messenger; Signal Transduction; Up-Regulation | 2019 |